Evidence map›Paper›PMID 32655659›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2020

Antinociceptive Effects of Shenling Baizhu through PI3K-Akt-mTOR Signaling Pathway in a Mouse Model of Bone Metastasis with Small-Cell Lung Cancer.

Zhe Feng, Ziyi Feng, Jie Han, Weimin Cheng, Bo Su, Jian Mo, XinJian Feng, Sitan Feng, GuoJian Chen, Peng Huang and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Zhe FengDepartment of Sports and Joint Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.ORCID https://orcid.org/0000-0001-5625-1501
Ziyi FengGuangxi University of Chinese Medicine, Nanning, China.ORCID https://orcid.org/0000-0003-3299-4567
Jie HanDepartment of Sports and Joint Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.ORCID https://orcid.org/0000-0003-1750-4400
Weimin ChengDepartment of Blood Specialty, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China.ORCID https://orcid.org/0000-0003-0069-2564
Bo SuDepartment of Sports and Joint Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.ORCID https://orcid.org/0000-0002-7309-8083
Jian MoDepartment of Sports and Joint Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.ORCID https://orcid.org/0000-0002-1942-3105
XinJian FengDepartment of Sports and Joint Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.ORCID https://orcid.org/0000-0002-4206-5385
Sitan FengDepartment of Sports and Joint Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.ORCID https://orcid.org/0000-0002-9923-7774
GuoJian ChenGuangxi University of Chinese Medicine, Nanning, China.ORCID https://orcid.org/0000-0002-2430-8312
Peng HuangGuangxi University of Chinese Medicine, Nanning, China.ORCID https://orcid.org/0000-0001-5526-0238
Long HuangGuangxi University of Chinese Medicine, Nanning, China.
Zhenwei CuiGuangxi University of Chinese Medicine, Nanning, China.ORCID https://orcid.org/0000-0001-8261-5559
Guangxi University · CNGuangxi University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shenling Baizhu additive powder (SLBZ-AP), a formulation of a variety of natural medicinal plants, has clinical efficacy in treating cancers in previous studies. We explored the effect of SLBZ-AP in bone metastasis of lung cancer (BMLC) mice, and the possible mechanism involved was further investigated in the present study. Mice model of BMLC was made and treated with SLBZ-AP. Pain behavioral tests were performed to explore the effect on BMLC-induced pain in mice. TUNEL staining was used to investigate apoptosis. The mRNA expression of markers in the PI3K/Akt/mTOR pathway was measured by qPCR, and protein expression was detected by western blotting and immunohistochemistry analysis. SLBZ-AP relieved BMLC-induced pain and prolonged animals' survival, promoted cell apoptosis in the marrow from the tibia of BMLC mice, and inhibited mRNA and protein expression of AKT, mTOR, P70S6, and VEGF, as well as protein expression of p-AKT, p-mTOR, p-P70S6, and VEGF upregulation in the marrow of tibia induced by BMLC, an effect which was similar to rapamycin. Our results suggested that SLBZ-AP may have antinociceptive effect and prolong survival of BMLC mice at least partially by inhibiting cell proliferation and promoting apoptosis through the PI3K/Akt/mTOR signaling pathway. SLBZ-AP may be a potential candidate for BMLC therapy.

Identifiers

PMID32655659
PMCPMC7327581
OpenAlexW3036507359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.